Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of lutropin alfa in poor ovarian responders undergoing controlled ovarian stimulation
2017-004298-15Phase 3Recruiting
- Sponsor
- International Vaccine Institute
- Start
- Aug 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lutropin alfa in poor ovarian response (POR) (2 arms), sponsored by International Vaccine Institute. Primary endpoint: Number of oocytes retrieved. Started Aug 2018; status: recruiting.
02
Drugs
lutropin alfa
03
Conditions
poor ovarian response (POR)
Beyond the preview
Go deeper on 2017-004298-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004298-15.